Fig. 1: The clinical development pathway for a repurposed agent and the alternatives pursued if needed, to characterize the repurposed agent for the new indication. | Nature Communications

Fig. 1: The clinical development pathway for a repurposed agent and the alternatives pursued if needed, to characterize the repurposed agent for the new indication.

From: Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders

Fig. 1

After entering at Phase 2 or Phase 3, reverse translation may be needed to resolve dosing or safety issues in Phase 1 studies or mechanistic questions in non-clinical studies (copyright J Cummings; Illustrator M de la Flor, phD).

Back to article page